Abstract
Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the development and progression of diabetic micro- and macroangiopathy. Among various metabolic derangements implicated in the pathogenesis of diabetic vascular complication, advanced glycation end product (AGE) hypothesis is most compatible with the theory of hyperglycemic memory. In this review, we discuss the molecular mechanisms of diabetic vascular complication, specially focusing on AGEs and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here.
Keywords: diabetic vascular complications, atherosclerosis, ages, oxidative stress, rage, renin-angiotensin system, insulin resistance, pigment epithelium-derived factor
Current Diabetes Reviews
Title: Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications
Volume: 1 Issue: 1
Author(s): Sho-ichi Yamagishi, Kazuo Nakamura and Tsutomu Imaizumi
Affiliation:
Keywords: diabetic vascular complications, atherosclerosis, ages, oxidative stress, rage, renin-angiotensin system, insulin resistance, pigment epithelium-derived factor
Abstract: Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the development and progression of diabetic micro- and macroangiopathy. Among various metabolic derangements implicated in the pathogenesis of diabetic vascular complication, advanced glycation end product (AGE) hypothesis is most compatible with the theory of hyperglycemic memory. In this review, we discuss the molecular mechanisms of diabetic vascular complication, specially focusing on AGEs and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Nakamura Kazuo and Imaizumi Tsutomu, Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications, Current Diabetes Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573399052952631
DOI https://dx.doi.org/10.2174/1573399052952631 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Importance, Pharmacological Activities and Analytical Aspects
of a Flavonoid Glycoside ‘Nicotiflorin’ in the Medicine
Drug Metabolism and Bioanalysis Letters Dolichol: A Natural Biomarker of Aging Endowed With a Photoenhanced Highly-Effective Solar Filter Activity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001)
Current Nutrition & Food Science Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Signal Transduction Inhibitors as Radiosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Novel Subtype Specific and Universal Somatostatin Analogues: Clinical Potential and Pitfalls
Current Pharmaceutical Design Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents
Current Pharmaceutical Design Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Can Anti-Thyroid Antibodies Influence the Outcome of Primary Chronic Immune Thrombocytopenia in Children?
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs in Noise-Induced Hearing Loss and their Regulation by Oxidative Stress and Inflammation
Current Drug Targets The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease
Current Pharmaceutical Design Clinically Significant Proteinuria Following the Administration of Sirolimus to Renal Transplant Recipients
Drug Metabolism Letters Central Amylin Signaling and the Regulation of Energy Homeostasis
Current Pharmaceutical Design Safety of Nanoparticles in Medicine
Current Drug Targets Intracoronary Brachytherapy - Clinical State and Pathophysiological Considerations
Current Pharmaceutical Design Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer
Mini-Reviews in Medicinal Chemistry Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Gestational Diabetes Mellitus: A Review from 2004
Current Diabetes Reviews